Jan Sun
Amgen
4 Papers
1 Citations
Jan Sun is an academic researcher from Amgen. The author has contributed to research in topics: Intrinsic apoptosis & Apoptosis. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.
Sean Caenepeel,Sean P. Brown,Brian Belmontes,Gordon Moody,Kathleen S. Keegan,Danny Chui,Douglas A. Whittington,Xin Huang,Leszek Poppe,Alan C. Cheng,Mario G. Cardozo,Jonathan B. Houze,Yunxiao Li,Brian Lucas,Nick A. Paras,Xianghong Wang,Joshua Taygerly,Marc Vimolratana,Manuel Zancanella,Liusheng Zhu,Elaina Cajulis,Tao Osgood,Jan Sun,Leah J. Damon,Regina K. Egan,Patricia Greninger,Joseph McClanaghan,Jia-Nan Gong,Jia-Nan Gong,Donia M Moujalled,Giovanna Pomilio,Pedro J. Beltran,Cyril H. Benes,Andrew W. Roberts,David C.S. Huang,David C.S. Huang,Andrew H. Wei,Jude Canon,Angela Coxon,Paul E. Hughes +39 more
TL;DR: AMG 176 is a potent, selective, and orally bioavailable MCL1 inhibitor that induces a rapid commitment to apoptosis in models of hematologic malignancies and the synergistic combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses.
382
Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy
Hanqiu Zheng,Yangjin Bae,Sabine Kasimir-Bauer,Rebecca Tang,Jin Chen,Guangwen Ren,Min Yuan,Mark Esposito,Wenyang Li,Yong Wei,Minhong Shen,Lanjing Zhang,Nikolai Tupitsyn,Klaus Pantel,Chadwick T. King,Jan Sun,Jodi Moriguchi,Helen Toni Jun,Angela Coxon,Brendan Lee,Yibin Kang,Yibin Kang +21 more
TL;DR: 15D11 dramatically sensitizes bone metastasis to chemotherapy, which induces Jagged1 expression in osteoblasts to provide a survival niche for cancer cells, establishing 15D11 as a potential therapeutic agent for the prevention or treatment ofBone metastasis.
153
Abstract LB-311: Inhibition of angiopoietin and Dll4 signaling in the tumor vasculature leads to increased efficacy in mouse tumor xenograft models
Angela Coxon,Paula Kaplan-Lefko,Stephen Kaufman,Jodi Moriguchi,Jan Sun,Beth Ziegler,William Wayne,Juan Estrada,Jenni Lavallee,Cindy Park,Taruna Arora,Teresa L. Burgess,Toni Jun +12 more
TL;DR: Combined inhibition of the angiopoietin/Tie2 and Dll4/Notch pathways does not interfere with their individual mechanisms of action and furthermore, leads to enhanced efficacy in preclinical models, suggesting the combination of these agents may have the potential to provide an expanded therapeutic opportunity to inhibit tumor angiogenesis beyond either individual agent alone.
1
Abstract 2027: Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models
TL;DR: This study evaluated the in vitro and in vivo activity of AMG 176, a potent and selective Mcl-1 inhibitor currently in Phase I clinical development, and revealed a rapid induction of apoptosis and loss of viability in M cl-1 dependent multiple myeloma and AML cell lines.